Premium
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data
Author(s) -
Conrado Daniela J.,
Duvvuri Sridhar,
Geerts Hugo,
Burton Jackson,
Biesdorf Carla,
Ahamadi Malidi,
Macha Sreeraj,
Hather Gregory,
Francisco Morales Juan,
Podichetty Jagdeep,
Nicholas Timothy,
Stephenson Diane,
Trame Mirjam,
Romero Klaus,
Corrigan Brian
Publication year - 2020
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1782
Subject(s) - dementia , leverage (statistics) , drug development , disease , drug , medicine , drug discovery , alzheimer's disease , data science , computer science , bioinformatics , pharmacology , artificial intelligence , biology , pathology
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. With 35 million people over 60 years of age with dementia, there is an urgent need to develop new treatments for AD. To streamline this process, it is imperative to apply insights and learnings from past failures to future drug development programs. In the present work, we focus on how modeling and simulation tools can leverage open data to address drug development challenges in AD.